Table 3.
Chemotherapy in Colorectal Cancer with Microsatellite Instability
| First author | Year | Study design | Adjuvant chemotherapy regimen | No. of patients (MSI/MSS) | Benefit of chemotherapy in patients with MSI |
|---|---|---|---|---|---|
| Elsaleh135 | 2000 | Consecutive patients | 5-FU | 63/669 | Yes |
| Ribic141 | 2003 | Randomized controlled study | 5-FU | 95/475 | No |
| Carethers94 | 2004 | Consecutive patients | 5-FU | 36/168 | No |
| de Vos tot Nederveen Cappel143 | 2004 | Lynch syndrome patients | 5-FU | 28/0 | No |
| Storojeva136 | 2005 | Randomized controlled study | 5-FU/mitomycin | 21/139 | No |
| Benatti142 | 2005 | Consecutive patients | 5-FU | 256/1007 | No |
| Popat51 | 2005 | Pooled data from multiple studies | 5-FU | 1277/6365 | No |
| Lanza137 | 2006 | Consecutive patients | 5-FU | 75/288 | No |
| Jover138 | 2006 | Consecutive patients | 5-FU | 66/688 | No |
| Kim126 | 2007 | Prospective study | 5-FU/leuocovorin | 98/444 | No |
| Des Guetz139 | 2009 | Meta-analysis | — | 454/2871 | No |
| Bertagnolli140 | 2009 | Randomized controlled study | 5-FU/irinotecan/leucovorin | 106/677 | No |
5-FU, 5-fluorouracil; MSS, microsatellite stable.